SS 15 - GU 3: Prostate Cancer Treatment Intensification

Moderator(s)

• TR

  Tyler Robin, MD, PhD

  University of Colorado School of Medicine, Department of Radiation Oncology
  Aurora, Colorado, United States
• 

  Alison Tree, MD, MBBS, BSc, FRCR, MD(Res)

  The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research
  London, London

Presentations:

• 10:45 AM – 10:55 AM ET

  Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus
  

  Presenter: Karen Hoffman, MD, FASTRO – MD Anderson Cancer Center
• 10:55 AM – 11:05 AM ET

  Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
  

  Presenter: Noelia Sanmamed, MD, PhD – Hospital Clinico San Carlos
• 11:05 AM – 11:15 AM ET

  Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher - Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials
  

  Presenter: Martin King, MD, PhD – Brigham and Womens Hospital
• 11:15 AM – 11:25 AM ET

  A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High Risk Prostate Cancer: Efficacy Results at Median 6 Y
  

  Presenter: Juanita Crook, MD – BCCancer
• 11:25 AM – 11:35 AM ET

  Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial
  

  Presenter: Comron Hassanzadeh, MD, MPH – MD Anderson Cancer Center
• 11:35 AM – 11:45 AM ET

  Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses
  

  Presenter: Colin Belliveau, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)
• 11:45 AM – 11:55 AM ET

  Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial
  

  Presenter: John Michael Bryant, MD – Moffitt Cancer Center